Duan M Q, Byers Robert A, Danby Simon G, Sahib Sura, Cha Amy, Zang Chuanbo, Werth John, Adiri Roni, Taylor Rosie N, Cork Michael J, Matcher Stephen J
Department of Electronic and Electrical Engineering, The University of Sheffield, The Kroto Building, Broad Lane, Sheffield, S3 7HQ, UK.
Sheffield Dermatology Research, Department of Infection and Immunity and Cardiovascular Disease, The University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK.
Biomed Opt Express. 2023 Jul 14;14(8):4126-4136. doi: 10.1364/BOE.494464. eCollection 2023 Aug 1.
Crisaborole 2% ointment is a non-steroidal treatment for mild-moderate atopic dermatitis (AD) and may produce fewer adverse effects than topical corticosteroids (TCS). We used PS-OCT to quantify dermal collagen at baseline and after 29 days of treatment with crisaborole and betamethasone valerate (BMV), in 32 subjects. PS-OCT detected a mean increase 1 × 10-6, 95% CI (6.3, 1.37) × 10-6 in dermal birefringence following TCS use (p < 0.0001, ad-hoc, not powered), whereas a change of -4 × 10-6, 95% CI (-32, 24) × 10-6 was detected for crisaborole (p = 0.77, ad-hoc, not powered). These results could suggest a differential effect on dermal collagen between the two compounds. PS-OCT may thus find an important role in safety assessment of novel AD treatment' and larger trials are warranted.
2%克立硼罗软膏是一种用于治疗轻中度特应性皮炎（AD）的非甾体药物，与外用糖皮质激素（TCS）相比，其产生的不良反应可能更少。我们使用偏振敏感光学相干断层扫描（PS-OCT）对32名受试者在基线时以及使用克立硼罗和戊酸倍他米松（BMV）治疗29天后的真皮胶原蛋白进行定量分析。PS-OCT检测到使用TCS后真皮双折射平均增加1×10⁻⁶，95%置信区间（6.3，1.37）×10⁻⁶（p<0.0001，临时分析，未计算效能），而克立硼罗组检测到的变化为-4×10⁻⁶，95%置信区间（-32，24）×10⁻⁶（p=0.77，临时分析，未计算效能）。这些结果可能表明这两种化合物对真皮胶原蛋白的作用存在差异。因此，PS-OCT可能在新型AD治疗的安全性评估中发挥重要作用，有必要开展更大规模的试验。
